Howard Streicher

7PUBLICATIONS
45CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 20, 2025
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma.

Ahmad A Tarhini, Alyssa Obermayer, Sandra J Lee

|Apr 04, 2025
Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".

Bhavana Konda, Eric J Sherman, Erminia Massarelli

|Nov 20, 2024
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors.

Megan Othus, Sandip P Patel, Young Kwang Chae

|Nov 19, 2024
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers.

Young Kwang Chae, Lucy Corthell, Sandip Pravin Patel

|Oct 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.

Young Kwang Chae, Megan Othus, Sandip Pravin Patel

|Aug 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.

Bhavana Konda, Eric J Sherman, Erminia Massarelli

Pageof 2

Frequent Collaborators

4 joint publications

Megan Othus

4 joint publications

Razelle Kurzrock

3 joint publications

Young Kwang Chae

3 joint publications

Sandip Pravin Patel